| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6156883 | American Journal of Kidney Diseases | 2015 | 8 Pages |
Abstract
A 10-mg dose of rivaroxaban in hemodialysis patients without residual kidney function results in drug exposure similar as published for 20Â mg in healthy volunteers. Rivaroxaban is not eliminated by dialysis. There is no accumulation after multiple daily dosing. The efficacy and safety of rivaroxaban in hemodialysis patients should be the subject of a large randomized trial.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
An S. MD, PhD, Rogier MD, Els MD, Dirk PhD, Daniëlle PhD, Bruno MD, PhD, Stefaan J. MD, PhD, Jan MD, PhD,